SG Americas Securities LLC increased its stake in shares of Medidata Solutions Inc (NASDAQ:MDSO) by 882.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 186,773 shares of the company’s stock after acquiring an additional 167,754 shares during the period. SG Americas Securities LLC owned about 0.30% of Medidata Solutions worth $13,679,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently bought and sold shares of MDSO. Dimensional Fund Advisors LP increased its position in Medidata Solutions by 6.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 143,913 shares of the company’s stock worth $10,551,000 after purchasing an additional 9,333 shares in the last quarter. LPL Financial LLC increased its position in Medidata Solutions by 25.2% during the 3rd quarter. LPL Financial LLC now owns 15,840 shares of the company’s stock worth $1,161,000 after purchasing an additional 3,185 shares in the last quarter. Man Group plc acquired a new position in Medidata Solutions during the 3rd quarter worth approximately $205,000. Thrivent Financial for Lutherans increased its position in Medidata Solutions by 5.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 14,280 shares of the company’s stock worth $1,047,000 after purchasing an additional 787 shares in the last quarter. Finally, Macquarie Group Ltd. increased its position in Medidata Solutions by 7.0% during the 3rd quarter. Macquarie Group Ltd. now owns 24,834 shares of the company’s stock worth $1,821,000 after purchasing an additional 1,616 shares in the last quarter.
In other news, EVP Daniel Patrick Shannon sold 19,725 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $75.17, for a total transaction of $1,482,728.25. Following the completion of the sale, the executive vice president now directly owns 70,497 shares in the company, valued at $5,299,259.49. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Michael Pray sold 15,000 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $76.50, for a total transaction of $1,147,500.00. Following the sale, the executive vice president now owns 77,134 shares of the company’s stock, valued at $5,900,751. The disclosure for this sale can be found here. Corporate insiders own 4.70% of the company’s stock.
NASDAQ MDSO traded up $0.75 on Wednesday, hitting $91.67. The company’s stock had a trading volume of 477,333 shares, compared to its average volume of 688,920. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.71 and a current ratio of 2.57. Medidata Solutions Inc has a 1-year low of $60.10 and a 1-year high of $98.60. The stock has a market cap of $5.63 billion, a P/E ratio of 95.49, a price-to-earnings-growth ratio of 8.20 and a beta of 1.42.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.33. Medidata Solutions had a net margin of 7.99% and a return on equity of 9.28%. The firm had revenue of $173.50 million during the quarter, compared to analysts’ expectations of $172.12 million. During the same period in the prior year, the company posted $0.40 EPS. The company’s revenue was up 16.3% on a year-over-year basis. Analysts predict that Medidata Solutions Inc will post 0.79 earnings per share for the current fiscal year.
A number of equities analysts recently issued reports on the stock. Dougherty & Co cut shares of Medidata Solutions from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 1st. Piper Jaffray Companies upped their price objective on shares of Medidata Solutions from $83.00 to $96.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 30th. SunTrust Banks cut shares of Medidata Solutions from a “buy” rating to a “hold” rating and set a $79.00 price objective for the company. in a research report on Wednesday, April 24th. Wells Fargo & Co cut shares of Medidata Solutions from an “outperform” rating to a “market perform” rating and set a $90.00 price target for the company. in a research report on Tuesday, April 23rd. Finally, Guggenheim began coverage on shares of Medidata Solutions in a research report on Wednesday, April 17th. They issued a “buy” rating and a $92.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $84.28.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Featured Story: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.